Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances

ROCKET PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$2.11

Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.
Cash $235.7M as of Sept 30; expects runway into 2026.
R&D expenses $133.9M (down from $144.6M); G&A $76.6M (up from $51.8M) due to commercial prep.
Completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease; dosing ongoing.
Initiated rolling BLA for RP-L102 for Fanconi Anemia; FDA approval for KRESLADI anticipated 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.